Fluocinolone acetonide

Fluocinolone acetonide
Systematic (IUPAC) name
(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
Clinical data
AHFS/Drugs.com International Drug Names
  • C
  • Prescription Only
Topical
Pharmacokinetic data
Metabolism Hepatic, CYP3A4-mediated
Half-life 1.3 to 1.7 hours
Identifiers
67-73-2 Yes
C05AA10 D07AC04 S01BA15 S02BA08
PubChem CID 6215
DrugBank DB00591 Yes
ChemSpider 5980 Yes
UNII 0CD5FD6S2M Yes
KEGG D01825 Yes
ChEBI CHEBI:31623 
ChEMBL CHEMBL989 Yes
Chemical data
Formula C24H30F2O6
452.488 g/mol
  (what is this?)  (verify)

Fluocinolone acetonide is a corticosteroid primarily used in dermatology to reduce skin inflammation and relieve itching. It is a synthetic hydrocortisone derivative. The fluorine substitution at position 9 in the steroid nucleus greatly enhances its activity. It was first synthesized in 1959 in the Research Department of Syntex Laboratories S.A. Mexico City.[1] Preparations containing it were first marketed under the name Synalar. A typical dosage strength used in dermatology is 0.01–0.025%. One such cream is sold under the brand name Flucort-N and includes the antibiotic neomycin.

Fluocinolone acetonide was also found to strongly potentiate TGF-β-associated chondrogenesis of bone marrow mesenchymal stem/progenitor cells, by increasing the levels of collagen type II by more than 100 fold compared to the widely used dexamethasone.[2]

Flucinolone is a group IV (0.01-0.2%) or group V (0.025%) corticosteroid under US classification.

See also

References

  1. J S Mills, A. Bowers, Carl Djerassi and H.J. Ringold, Steroids CXXXVII. Synthesis of a New Class of Potent Cortical Hormones. 6α,9α-Difluoro-16α-Hydroxyprednisolone and its Acetonide, Journal of the American Chemical Society, 80, 3399-3404 (1960)
  2. Hara ES, Ono M, Hai PT, Sonoyama W, Kubota S, Takigawa M, Matsumoto T, Young MF, Olsen BR, Kuboki T. Fluocinolone Acetonide is a Potent Synergistic Factor of TGF-β3-Associated Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells for Articular Surface Regeneration. J Bone Miner Res. 2015. http://onlinelibrary.wiley.com/doi/10.1002/jbmr.2502/abstract